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ABSTRACT
Introduction Antimicrobial resistance (AMR) is a global 
health threat that requires urgent research using a 
multidisciplinary approach. The biological drivers of AMR 
are well understood, but factors related to treatment 
seeking and the social contexts of antibiotic (AB) use 
behaviours are less understood. Here we describe the 
Holistic Approach to Unravel Antibacterial Resistance in 
East Africa, a multicentre consortium that investigates the 
diverse drivers of drug resistance in urinary tract infections 
(UTIs) in East Africa.
Methods and analysis This study will take place in 
Uganda, Kenya and Tanzania. We will conduct geospatial 
mapping of AB sellers, and conduct mystery client 
studies and in- depth interviews (IDIs) with drug sellers 
to investigate AB provision practices. In parallel, we will 
conduct IDIs with doctors, alongside community focus 
groups. Clinically diagnosed patients with UTI will be 
recruited from healthcare centres, provide urine samples 
and complete a questionnaire capturing retrospective 
treatment pathways, sociodemographic characteristics, 
attitudes and knowledge. Bacterial isolates from urine 
and stool samples will be subject to culture and antibiotic 
sensitivity testing. Genomic DNA from bacterial isolates 
will be extracted with a subset being sequenced. A follow- 
up household interview will be conducted with 1800 UTI- 
positive patients, where further environmental samples will 
be collected. A subsample of patients will be interviewed 
using qualitative tools. Questionnaire data, microbiological 
analysis and qualitative data will be linked at the individual 
level. Quantitative data will be analysed using statistical 
modelling, including Bayesian network analysis, and 
all forms of qualitative data analysed through iterative 
thematic content analysis.
Ethics and dissemination Approvals have been obtained 
from all national and local ethical review bodies in 
East Africa and the UK. Results will be disseminated in 
communities, with local and global policy stakeholders, 
and in academic circles. They will have great potential to 
inform policy, improve clinical practice and build regional 
pathogen surveillance capacity.
INTRODUCTION
Antimicrobial resistance (AMR) emerges 
when pathogens evolve ways to survive treat-
ments (ie, antibiotic (AB), antiprotozoal, 
antiviral and antifungal medicines). Antibi-
otic resistance (ABR) is a significant subset 
of this phenomenon and is the focus of this 
study. Increasing levels of resistance to ABs 
(ABs in this study is specifically used to refer 
to drugs with antibacterial activity) are a 
Strengths and limitations of this study
 ► Multisite, multicountry study with harmonised tools 
providing opportunity for contextual comparisons.
 ► Provides novel linkage at the patient level between 
treatment pathways, sociodemographics, knowl-
edge and attitudes, and pathogen characteristics 
(antibiotic (AB) susceptibility and genetic profile).
 ► Describes the AB provision landscape context of the 
patients through using geospatial mapping, mystery 
client and qualitative interviews.
 ► Patient sample is representative of a population of 
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serious threat to global health and, if no action is taken, 
are projected to cause 10 million excess deaths by 2050.1 It 
is unlikely that this burden will be evenly distributed, and 
Africa is particularly vulnerable to the challenges posed 
by AMR/ABR since the continent suffers the highest 
morbidity and mortality arising from infectious diseases 
and the least developed laboratory infrastructure.2 The 
economic, cultural and ethnic diversity of Africa means 
that the problems surrounding drug resistance are likely 
both to be distinct from other regions of the world and 
to display significant intracontinental diversity. Regional 
solutions and local approaches are necessary.
Beyond the microbiological and biological origins of 
ABR and AMR, there are biosocial problems requiring an 
interdisciplinary approach that incorporate social science 
perspectives on human–microbial interactions.3 Despite 
this, social science perspectives on the evolution and 
control of AMR are rare.4 While the biological drivers of 
AMR in pathogens are well explored,5 the extent to which 
these are modulated by human behaviour in and around 
ABs is less well understood. Cultural, social, economic 
and clinical factors play a part in shaping the way people 
source, consume, use and distribute ABs.6 More effective 
AB stewardship is acknowledged as one of the key inter-
ventions to preserve existing ABs. If this is to be achieved, 
then we must address the knowledge gap of structural 
factors and social behaviours that drive pathogens’ AB 
selection pressure and, ultimately, genetic changes in 
pathogens. Such a problem cannot be achieved by one 
scientific discipline acting alone. Rather, this complex, 
multifaceted problem requires an integrative approach 
able to work effectively across disciplines.
Here, we describe a newly formed consortium—the 
Holistic Approach to Unravel Antibacterial Resistance 
(HATUA). The consortium brings together expertise in 
microbiology, pathogen genomics, epidemiology, human 
geography, anthropology, sociology, computational 
biology and statistics across seven institutions, from three 
East African countries (EACs), the UK and the USA. 
Taking hatua (a Kiswahili word for ‘step’ or ‘action’) as 
inspiration for its acronym, the consortium addresses 
the social and biological drivers of AB drug resistance in 
multiple sites in Kenya, Tanzania and Uganda, using the 
clinical prism of urinary tract infection (UTI). UTIs are 
common globally, and, in low- income and middle- income 
countries rarely have a laboratory diagnosis. Moreover, 
they are often mistaken for other illnesses such as sexually 
transmitted infections (STIs), and consequently remain 
poorly treated.7 8 Through synthesis across multiple sites 
of our study of the burden and drivers of ABR at national 
and regional levels, we will provide insights on ABR 
emergence that may be applicable to other diseases and 
contexts.
The research will focus on four key elements of the ABR 
problem in UTI: the therapy landscape, the pathogen, 
the patient and the community. The research will target 
three main (inter- related) drivers: first, the supply of ABs; 
second, the level of knowledge of proper use of ABs; and 
third, the choice of AB by clinicians and patients and rela-
tive effectiveness of treatment. In each case, we will bring 
novel methodological and theoretical approaches to bear 
on the issues. Our work will deliver a unique research 
dataset that links patients, the pathogen and the socio-
economic and sociodemographic picture of the indi-
vidual and their community. Through our research and 
impact activities, we will also strengthen diagnostic and 
analytical capacity, and dynamic pathogen surveillance in 
the region.
Theoretical and conceptual framework
A challenge of interdisciplinary working is not neces-
sarily finding commonly understood methodologies but 
shared theoretical (ontological and epistemological) 
frameworks. This is a theme with which the ‘one health’ 
paradigm must grapple if it wishes to understand how 
infectious disease processes are products of both biolog-
ical and social relations.9 In this study, we conceptualise 
the drivers of AB- resistant UTI infections as part of a 
complex system of inter- relating biological and social enti-
ties,10 drawing theoretical inspiration from assemblage 
theory, which facilitates the incorporation of a range of 
different material actors/actants (humans, animals and 
microbes) in a single dynamic system.11 Its advantage is 
that it encourages experimentalists to engage with the 
conscious human decision- making in biosocial systems. 
This approach encourages social scientists to take an 
‘ontological turn’, recognising that ‘inanimate’ material 
things (be they bacteria, drugs or clinics) are not merely 
inert unless given meaning by human subjects, but are 
themselves able to animate and produce effects.12 Conse-
quently, we argue that ‘new materialist’ approaches13 
provide an ideal framework for conceptualising ABR as 
a complex assemblage of human and non- human entities 
operating at various scales.
In developing our study, we reviewed the extant liter-
ature on possible social and biological drivers and 
constructed a representation of a UTI- related ABR assem-
blage (see simplified version figure 1) . The representa-
tion maintains the false poles of ‘social’ and ‘biological’ 
but only to emphasise the importance of exploring the 
integration of sociobiological factors that facilitate ABR. 
We know that AB suppress bacteria exerting selection 
pressure that results in the development of ABR (figure 1, 
blue/right), but some of the drivers of this process lie in 
the social realm (figure 1, white/left). The behaviours of 
individual agents, such as healthcare workers, patients and 
those in the community, are situated within the structures 
and institutions that shape them. For example, improve-
ments in structural inequalities around water, sanitation 
and hygiene at the household or community scale might 
reduce the development of UTIs and the need for antimi-
crobial use in the first place,14 removing one significant 
driver of ABR selective pressure.
Previous research has focused on challenges faced by 
clinicians in attempting to prescribe antimicrobials effec-
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However, in EAC, pharmacies, drug shops and other 
informal sellers are ubiquitous, existing side by side with 
the public and private healthcare systems, other providers 
such as traditional healers and veterinary providers. With 
such medical pluralism, non- prescription dispensing 
of antimicrobials for self- medication is extremely 
common,16 17 influenced not only by individual- level abil-
ities but also by larger social and regulatory structures.
At the centre of this assemblage (figure 1), we identify a 
‘new material’ nexus (coloured grey) consisting of critical 
practices (such as dispensing, AB use in animals and AB 
stewardship practices) and the treatment- seeking path-
ways of patients with UTI. This central nexus describes 
the entanglement of sociobiological processes that likely 
drive selective pressure in bacteria and thence develop-
ment of ABR UTI. A focus for HATUA is to describe and 
investigate the social and biological drivers of patients’ 
treatment- seeking pathways, or ‘patient pathways’, and 
how these relate to patterns of ABR at individual and 
community levels. We conceptualise a patient pathway 
as a longitudinal sequence of health- seeking behaviours 
taken by individuals when they feel ill, which might 
include delays in seeking treatment, self- medication,18 
attending various formal and informal healthcare 
providers, and taking medications more or less appropri-
ately. These pathways may be complex, non- linear and, 
given the economic and sociocultural barriers to clinically 
ideal pathways, iterative. Rather than theorise health-
care decision making as patients freely and rationally 
choosing from a suite of available options, pathway- based 
models view behaviour as a sequence of steps each with 
its own situated rationality, and set of social dependen-
cies, constraints and inter- relationships.19 20 This draws 
on concepts of ‘medical syncretism’, which describe how 
patients may oscillate between different types of health-
care in a single illness episode.21 Requiring detailed 
longitudinal analysis, this approach has most often been 
operationalised using qualitative interviews, as in the case 
of abortion- related care,22–24 and quantitative approaches 
are rare.25–27 In this study, we collect large- scale quantita-
tive data alongside qualitative in- depth interviews (IDIs), 
which are linked to individual- level pathogen and ABR 
profiles.
Pilot phase 2017–2018
HATUA pilot activities in 2017–2018 in Uganda and 
Kenya aimed to develop capacity and to demonstrate the 
feasibility of the holistic study design by conducting a 
study of microbiological and genomic features of urinary 
pathogens collected from clinic patients, combined with 
quantitative sociodemographic data. Patients with UTI- 
like symptoms were recruited in public clinics and hospi-
tals in Nairobi, Kenya and Isingiro District, Uganda, and 
provided bacterial samples (most commonly urine, but 
also stool). In Uganda, 129 of these patients (or their 
guardians) also completed questionnaires capturing 
their sociodemographic features, AB knowledge and 
behavioural characteristics (see summary in online 
supplemental appendix A, table A1). While the sample 
size for the questionnaire was not sufficient for detailed 
Figure 1 ABR assemblage (a complex set of inter- related factors) as it refers to UTI. AB, antibiotic; ABR, antibiotic resistance; 
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statistical analysis, the data indicated a higher proportion 
of women recruited than men (71% female), and the 
majority of patients were of working age. Over half of the 
respondents had taken medication in the last 6 months 
(55%), and of those who did, most obtained medications 
from clinics or health centres and nearly one- fifth (18%) 
from drug shops.
Urine samples were analysed using culture and antibi-
otic sensitivity testing (C&AST), and a total of 150 bacte-
rial isolates (n=91 from Kenya and n=59 from Uganda) 
were genomically characterised, which confirmed a high 
prevalence of uropathogenic strains Escherichia coli and 
Klebsiella pneumoniae, and revealed high levels of multi-
drug resistance mainly disseminated via clonal and hori-
zontal transfers (the full results are reported here28). 
This exploratory pilot study illustrated the feasibility of 
collecting linked microbiological, genomic and socio-
economic data, and highlighted important operational 
fieldwork issues regarding linkage and follow- up to the 
homestead.
We also conducted IDIs with healthcare providers 
(eg, nursing assistants) and four focus group discus-
sions (FGDs) with community members (mainly crop 
farmers and pastoralists) in Isingiro District, Uganda, to 
explore behaviours and attitudes to AB use and to iden-
tify possible drivers of ABR for hypothesis generation. 
These data were analysed using thematic content anal-
ysis, which highlighted potential drivers of ABR. Among 
community members, these included distrust and misuse 
of ABs, failure to complete treatment courses, human use 
of veterinary drugs and combined consumption of ABs 
and traditional medicines, which informed the develop-
ment of the research questions in the main study.
METHODS AND ANALYSIS: MAIN HATUA STUDY
Field activities and data collection
HATUA’s activity will take place in Kenya, Uganda and 
Tanzania, and multidisciplinary teams will sequen-
tially survey in three study areas (SAs) in each country 
(figure 2). The locations are sociodemographically 
distinct: (1) urban, economically advanced settings that 
potentially increase affordability and access to ABs; (2) 
remote villages in poorer areas where poverty, physical 
isolation and lower access to ABs possibly lead to potential 
drivers, such as sharing of prescriptions, restricted micro-
biological culture and poor AB sensitivity testing (C&AST) 
capacity; and (3) pastoralist and neglected network- areas 
with highly mobile pastoralist communities, and high 
levels of animal–human interaction fostering a zoonotic 
link. The tertiary hospital (level 5), and lower- level health-
care facilities in the SAs (level 4, 3 and 2 clinics/hospitals) 
will be used to recruit patients with UTI and also conduct 
interviews with healthcare providers (see work streams 
(WS) 1, 2 and 3 further). Beyond the hospitals, the activity 
will take place in the rest of the SA, visiting AB retailers, 
households and communities. At the start of activities in 
all SAs, community inception workshops will be held to 
introduce and communicate the goals of HATUA to rele-
vant stakeholders (the local community, village health 
teams, doctors, hospital and lab workers, and local health 
authorities). Sampling will begin in April 2019 in some 
sites and will continue through 2020 (COVID-19 permit-
ting). All data collection tools and operating protocols 
are standardised, allowing valid comparison across sites 
and countries. For collecting quantitative, social science 
and laboratory data and geospatial mapping, we will use 
EpiCollect 5 (https:// five. epicollect. net),29 a customis-
able mobile data gathering tool installed on tablets and 
mobile phones.
Recruitment of sample of patients with UTI
At the heart of the HATUA study will be a linked data 
set of 1800 patients (600 per country, 200 per site with 
culture- confirmed UTI (table 1). Given the estimated UTI 
prevalence from the pilot study, this will mean recruiting 
three times that number, c. 5400 patients. Sample size 
calculations were challenging, given the number of 
possible ways of measuring this, and limited evidence of 
different prevalence rates for community and hospital- 
acquired resistant UTI infections of adults and children 
in this region. To estimate precision, under a binomial 
model, the numbers required to obtain a 95% CI for the 
prevalence of 0.5 with width no greater than 0.1 would 
be a little under 400 (384). That model relies on there 
being no underlying population or sampling structure 
and so will lead to an underestimate of the true required 
Figure 2 Location of HATUA SAs. HATUA, Holistic 
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numbers in our complex study. Our larger study size of 
600 per country will provide some robustness to our ability 
to estimate this parameter with the desired accuracy while 
allowing us to uncover some of the population structures 
that, if modelled correctly, will improve the precision in 
our estimate of prevalence. In level 2, 3, 4 and 5 hospi-
tals in each SA, we will recruit adult and child outpatients 
(minimum of 90% of the total sample) that a doctor iden-
tifies as suffering with UTI- like symptoms (eg, burning/
irritation during urination, dysuria and pyuria). In level 
5 hospitals, we will also recruit inpatients (maximum of 
10% of the total). For non- pregnant child patients aged 
under 18 years, data will be provided by an accompanying 
parent or guardian. Our sample is representative only of 
the population of clinic attendees rather than the general 
population and is likely to include a higher proportion 
of patients with treatment failures who are wealthier and 
patients living closer to clinics. However, clinic attendees 
are an important patient subset as these are the individ-
uals specifically for whom clinicians must make patient 
management and treatment decisions.
A urine sample and, where possible, a faecal sample 
will be taken from all patients. From catheterised inpa-
tients, urine catheter samples will be gathered, whereas 
outpatients will be advised how to self- collect mid- stream 
urine samples. In addition, patients will have a question-
naire administered to collect retrospective data on their 
recent clinical history and related treatment seeking and 
AB usage (see figures 3 and 4 for the topics covered in the 
questionnaire). The questionnaire will capture individual- 
level sociodemographics (eg, age, gender, education, 
household and family circumstances), household socio-
economic factors (eg, housing type, amenities and asset 
ownership used to derive multidimensional poverty 
indices), treatment- seeking behaviours, attitudes towards 
medication, ABs and AMR, and residential geographical 
information.
During initial recruitment, all patients will be asked to 
provide consent to being followed up if they test positive 
for a UTI. Eligible outpatients with culture- confirmed 
UTI will be recontacted for a follow- up to their homes 
(see WS4). For logistical reasons, only patients living 
within an approximate distance of 70 km from the level 5 
hospital and 10 km from the level 4 and 3 hospitals will be 
eligible for follow- up. During follow- up a questionnaire 
will be administered to a competent adult member of the 
household to capture sanitation and hygiene, sociodemo-
graphics, economic and poverty dimensions, household 
Table 1 Target sample sizes for HATUA data collection tools
Per study site Per country 
total
Study
totalPhase 1 Phase 2 Total















Household questionnaire 100 100 200 600 1800
Patient IDIs 5 5 10 30 90
Healthcare worker IDIs 1–5 0–5 to fill 
quota
5 15 45
Drug seller mystery client study visits – 50 50 150 450
Drug seller IDIs – 10 10 30 90
Focus group discussions – 4–8 4–8 12–24 36–72
HATUA, Holistic Approach to Unravel Antibacterial Resistance in East Africa; IDI, in- depth interview; UTI, urinary tract infection.
Figure 3 Description of quantitative and qualitative data collected about the self- reported ‘patient pathway’ in the linked 
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health- seeking behaviour, and livestock keeping practices. 
Environmental sampling of soil, animal faecal samples 
and other materials in the immediate proximity of the 
home will be conducted using a variety of approaches, 
including toilet swabs and boot sock/swab sampling of 
the soil in and around the homestead. To enrich the 
quantitative data, a subsample of patients with UTI will 
be purposively selected for qualitative IDIs based on 
their having drug- resistant UTI pathogens or reporting 
complex patient treatment pathways (10 per SA, 90 in 
total). The qualitative interviews will be conducted using 
a standardised topic guide across sites, which covers 
experience of illness, stigma, patient pathway narratives, 
experience of the doctor’s consultation and subsequent 
steps, understanding of risk factors for UTI, AMR and AB 
stewardship.
The resulting qualitative and quantitative social 
science data and microbiological data will form an 
individual- level linked dataset. This will incorporate 
quantitative questionnaire data collected at the clinic 
and the home, qualitative data from IDIs, C&AST and 
whole- genome sequence (WGS) of pathogens from 
the patient, and C&AST from household samples (see 




Using EpiCollect on a GPS- enabled tablet, in all SAs, we 
will conduct geospatial mapping of observed AB providers 
in the local community (eg, from hospitals and clinics to 
retail pharmacies and informal drug sellers, to veterinary 
drug shops).
Mystery client study of drug sellers
A common means of reducing response bias from surveys 
is to use mystery client or simulated client studies to 
investigate ‘real- life’ dispensing practices of drugs sellers 
and pharmacies.17 30 Using the sampling frame created 
by the aforementioned geospatial mapping exercise, 
we will randomly select outlets to participate in a simu-
lated/mystery client study. Trained fieldworkers using 
predefined scenarios will request ABs and/or advice for 
the treatment of UTI- like symptoms. After the encounter, 
they will record data including whether and what kind of 
AB they were offered, the course and regimen they were 
sold, whether they were asked for a prescription, costs 
and advice given.
Qualitative IDIs with drug sellers
We will also select 10 drug sellers/ pharmacies per SA (see 
table 1) for qualitative IDIs to investigate their knowledge, 
motivations, attitudes and practices around AB provision 
and ABR. These will discuss the service they provide to 
the community, understanding and attitude to gover-
nance and AMR, and about the business and economic 
drivers of their work.
Qualitative IDIs with healthcare workers
In our recruitment hospitals/clinics, we will recruit 
trained clinical professionals using convenience sampling 
to investigate their knowledge and attitudes using qual-
itative IDIs (five per SA, 45 in total). The topic guide 
covers experience of UTI diagnosis and prescribing, 
knowledge, attitudes towards ‘AB stewardship’ and 
understandings of drivers of ABR, including economic 
and cultural issues.
Figure 4 Linked individual- level patient dataset collected in HATUA. AB, antibiotic; AMR, antimicrobial resistance; AST, 
antibiotic sensitivity testing; ESBL, extended spectrum beta- lactam resistance; HATUA, Holistic Approach to Unravel 
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Community focus groups
In each SA, age- specific and gender- specific community 
FGDs will be conducted (among non- study participants), 
selecting from a range of socioeconomic status groups. 
The topic guide will cover experience of illness, pathways 
to care, experience of healthcare services, accessing ABs, 
perceptions of AMR and AB stewardship. In total, up to 
24 FGDs per country will be conducted.
Patient and public involvement
In addition to the community focus groups conducted 
during pilot work, and the community inception work-
shops (detailed above), at the end of SA activities, we 
will use Community Dialogues (CDs) that bring together 
community members, health workers and veterinarians 
to a face- to- face engagement discussing the findings, and 
stimulate community participation and full engagement, 
and also identify how grassroots health workers might be 
used most effectively to improve ABR stewardship.
Research questions and data analysis plan
The main research questions and corresponding analyses 
are designed within five interlinked WSs.
WS1: the therapy landscape
This WS will investigate how ABs are provided and used in 
our SAs in a number of interlinked ways. First, by analysing 
the geospatial data collected on AB providers, we will 
describe the spatial distribution and density of drug- 
dispensing outlets in both formal and informal health-
care settings. Second, we will analyse the data from the 
mystery client studies geospatially. Third, by combining 
quantitative statistical analysis of the mystery client study 
with systematic thematic coding of the qualitative inter-
views, we will investigate the AB provision practices and 
knowledge among different AB providers. By developing 
an understanding of differences in the AB provision land-
scape and the knowledge, motivations and practices of 
AB sellers, we will seek to determine what factors regulate 
individual patient pathways to AB use.
WS2: pathogen
In this WS, we will confirm UTI, identify the pathogenic 
organisms present and determine the antimicrobial 
susceptibility. Urine samples from 1800 culture- confirmed 
patients with UTI will be analysed to investigate the 
burden of disease and resistance. Antibiotic sensitivity 
testing (AST) will be conducted on an agreed set of clin-
ically relevant ABs, along with special phenotypes such as 
extended- spectrum beta- lactam resistance (ESBL) (see 
online supplemental appendix B). The WHONET data 
capture and reporting software will be adopted in all SA 
hub laboratories, providing automated analysis of various 
multidrug- resistant phenotypes.
Genomic DNA of the samples will be extracted and 
sequenced. The resulting WGS libraries will be used to 
characterise the isolates and define pathogen population 
structures. We will identify the local and regional spread 
of ABR determinants and describe their evolutionary 
dynamics and local reservoirs among HATUA bacte-
rial populations. These data will be linked to patient 
and household sociodemographics to pinpoint possible 
drivers of resistance at patient, hospital and household 
levels. By comparing our collections with previously 
published genomes, high- risk clones and their poten-
tial origins will be determined and their spread mapped 
across space and time.
WS3: patient
This WS will investigate social, structural and behavioural 
drivers of ABR by identifying the various patient path-
ways to treatment and how these intersect with the ABR 
process. We will summarise quantitative pathway data 
using longitudinal latent class analysis and/or sequence 
analysis, and relate this statistically to ABR profiles at indi-
vidual and community levels. To identify how treatment 
pathways could become more clinically effective, we will 
combine quantitative and qualitative patient pathway 
data with IDIs from drug sellers and doctors to investigate 
sources of prescribed and non- prescribed ABs and prac-
tices, prevalence and determinants of self- medication, 
and how these are constituted.
WS4: community
In this WS, we will investigate social and community atti-
tudes to treatment seeking, AB use and ABR, and how 
community household level factors, including hygiene 
practices, health- related behaviour, livestock keeping 
practices and the household microbiological landscape, 
influence ABR and broader- risk burdens. Questions in 
the household questionnaire addressing AB use with 
animals and animal products will be statistically related to 
ABR burden in urine, faecal and environmental samples. 
We will also analyse relevant data gathered during patient 
IDIs and community focus groups, transcribed and trans-
lated by local translators and fieldworkers, using system-
atic thematic coding in NVivo to give us information 
about experiences of illness and localised rationales for 
treatment.
WS5: interdisciplinary synthesis
In this WS, we will integrate and synthesise the data 
collected in WS1–4 to explore how population and 
individual level behaviours and processes interact to 
contribute to the risk of ABR. Using the patient linked 
dataset, we will generate hypotheses about direct and 
indirect drivers of ABR using Bayesian network analysis.31 
We will use Bayesian networks to identify latent factors 
in different data types and then connect them with each 
other and key outcome variables in a heterogeneous 
network across all data. The network structure will iden-
tify direct and indirect influences on ABR, and Bayesian 
networks' probabilistic inference will predict the proba-
bility of impact on ABR of change in different drivers. 
Multilevel regression will then be used to identify which 
of these direct and indirect drivers account for the most 
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of modifications. Information about AB sensitivity of 
urinary pathogens will be blinded from fieldworkers 
conducting household visits and questionnaires and from 
microbiologists collecting environmental samples from 
households to ensure fidelity.
ETHICAL CONSIDERATIONS
Informed consent
Written informed consent will be obtained from all 
participants prior to any data or specimen collection, 
with the exception of drug sellers taking part in the 
mystery client study, for whom the process would inval-
idate the approach. Participants will provide consent 
for questionnaire- filling/interviewing/focus groups 
(including audio recording, which will be subsequently 
transcribed and translated by locally trained fieldworkers) 
and for sample collection and analysis, and shipment of 
samples to third- party labs for WGS. All patient samples 
will be non- invasive by urine and stool collection only. The 
principal language of recruitment and administration of 
the informed consent document (ICD) and the question-
naire will be the language used in hospitals (ie, Kiswahili 
for Kenya and Tanzania, and Luganda, Runyankole and 
Ngakarimojong for Uganda). Local translators will be 
used to draft the ICD, and ICD will be back -translated. 
The consent process will be administered by fieldworkers 
who understand the relevant languages and dialects.
Privacy and confidentiality
A number of procedures will be used to protect the confi-
dentiality of respondents and the information collected: 
(1) questionnaires/interviews will be conducted only in 
a private setting; (2) all interviewers will be trained in 
research ethics; (3) all data will be kept strictly confiden-
tial, and numerical IDs will be used in place of names on 
all of the data collection instruments. At each new step of 
data collection, participants will be informed of confiden-
tiality procedures during the consent process. All patients 
in the linked part of the study will be anonymised and 
identified through an eight- figure identifier and barcode 
to link social science and laboratory data effectively. Any 
personal data will be stored on handwritten consent 
forms securely and separately from questionnaire, test 
results and patient IDIs. EpiCollect data are uploaded to 
a secure cloud server. The reason for recruitment to the 
household follow- up will not be disclosed or discussed 
with anyone except the patient/respondent themselves. 
Geospatial data identifying home locations and drug 
sellers will be edited to avoid disclosure. Participants in 
other IDI and FGDs, together with data from mystery 
client visits, will be anonymised, and recordings, trans-
lations and transcriptions will be stored and transferred 
securely.
Ethics approvals
The study received ethical approval from the University of 
St Andrews, UK (number MD14548, 10/09/19); National 
Institute for Medical Research, Tanzania (number 2831, 
updated 26/07/19); CUHAS/BMC Research Ethics and 
Review Committee (number CREC /266/2018, updated 
on 02/2019); Mbeya Medical Research and Ethics 
Committee (number SZEC-2439/R.A/V.1/303030); Kili-
manjaro Christian Medical College, Tanzania (number 
2293, updated 14/08/19); Uganda National Council for 
Science and Technology (number HS2406, 18/06/18); 
Makerere University, Uganda (number 514, 25/04/18); 
and Kenya Medical Research Institute (04/06/19, Scien-
tific and Ethics Review Committee (SERU) number 
KEMRI/SERU/CMR/P00112/3865 V.1.2). For Uganda, 
administrative letters of support were obtained from 
the district health officers to allow the research to be 
conducted in the respective hospitals and health centres.
RESULT DISSEMINATION AND IMPACT
HATUA’s data will be available via an interactive website 
that will collate and present ABR data from across the 
EAC overlaid with socioeconomic, microbiological and 
genome data. Data will be visualised and shared in Micro-
react (https:// microreact. org).32 The consortium is part-
nered with the East African Health Research Commission, 
a statutory organ of the East African Community, which 
will spearhead the integration of HATUA outputs into 
policy at the regional level. In the near term, this will allow 
doctors to access information they can use to improve 
diagnosis and prescription patterns based on resistance 
profiles prevailing locally. In the longer term, HATUA 
will lay a strong foundation for a regional surveillance 
initiative and will provide a vital resource for regional 
ABR policy formulation. The results have great poten-
tial to inform policy, improve clinical practice and build 
capacity for pathogen surveillance in the region. The 
novel linked microbiological, genomic and social science 
data will provide new insights into social drivers of ABR.
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